13 March 2017
Cambridge, MA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has introduced Patient Profiles to its rapidly expanding platform. The powerful combination of Patient Profile reports, guided by CluePoints’ advanced central statistical monitoring, offers a new way for clinical teams to prioritize the investigation of atypical patients in clinical trials.
Patient Profiles provides detailed insight into patient experiences and offers a more targeted approach by identifying anomalies in data and ranking patients by their relative degree of atypicality. The highly configurable Patient Profiles solution presents a rich set of customizable visualization options, including the ability to visually assess a chronological view of a patient’s visit, investigational product exposure, adverse events and concomitant medications – along with any additional relevant patient information. The solution will help to enhance overall quality management, guiding study teams to quickly and effectively characterize risk signals and enable centralized medical and safety reviews within the CluePoints platform.
“The addition of Patient Profiles to CluePoints’ portfolio aligns with our vision of expanding data exploration capabilities at both the patient and site level,” commented Steve Young, chief operations officer at CluePoints. “Reinforced by the voice of our customers, the solution will revolutionize the patient profiles review process by prioritizing and illuminating ‘at risk’ patients.
“Our agile product methodology is enabling us to rapidly evolve our solutions and exceed the expectations of our customers, delivering tangible value to them. This latest addition will significantly improve the efficiency of patient data review processes because customers can target their efforts on the patients and data that matter most.”
For further information on CluePoints’ solutions, please visit www.cluepoints.com
About CluePoints
CluePoints® is a Risk-Based Monitoring and Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a Risk-Based Monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
Media contact
Patrick Hughes – Chief Commercial Officer, CluePoints
[email protected]
+44 (0) 7703 532 749
